...
机译:在疗法效益评估中存在不同随访时间的估价与不良事件的分析
Department of Medical StatisticsUniversity Medical Center GoettingenGoettingen Germany;
Center for Clinical TrialsUniversity Hospital EssenEssen Germany;
Biostatistics and Special Pharmacokinetics Unit Federal Institute for Drugs and Medical;
Institute of StatisticsUlm UniversityGermany;
Roche Pharma AGGrenzach Germany;
Bristol‐Myers Squibb GmbH &
Co. KGaAMünchen Germany;
Lilly Deutschland GmbHBad Homburg Germany;
Pfizer Deutschland GmbHBerlin Germany;
Merck KGaADarmstadt Germany;
Center for Clinical TrialsUniversity Hospital EssenEssen Germany;
Institute of Medical Biometry and InformaticsUniversity of HeidelbergHeidelberg Germany;
Clinical Trials Unit Faculty of Medicine and Medical CenterUniversity of FreiburgFreiburg im;
Schwenke Consulting: Strategies and Solutions in Statistics (SCO:SSIS)Berlin Germany;
Institute for Quality and Efficiency in Health CareCologne Germany;
AbbVie Deutschland GmbH &
Co. KGLudwigshafen Germany;
Boehringer Ingelheim Pharma GmbH &
Co. KGIngelheim Germany;
Department of Medical StatisticsUniversity Medical Center GoettingenGoettingen Germany;
adverse events; benefit assessment; clinical trials; estimands; safety data;
机译:在疗法效益评估中存在不同随访时间的估价与不良事件的分析
机译:不同随访时间(Savvy)的不良事件的生存分析 - 反驳事件风险
机译:对药物效益评估中不良事件分析的生物学问题
机译:鉴定和跟进与NRTI使用相关的不良事件,在临床实践中导致其替代Tenofovir DF(RECORT SCHONE)。
机译:急性心肌梗死后坚持二级预防疗法的时变和时不变措施的影响:边缘结构模型(MSMs)的应用。
机译:在治疗获益评估中随着随访时间的变化对不良事件的估计和分析
机译:关于疗效评估不同随访时间内不良事件的估价与不良事件的分析
机译:assET(安全重大事件评估小组)对斯洛伐克Bohunice(1-2号机组)核电厂1993年7月5日至9日的后续访问的报告。对业务活动进行根本原因分析,以加强预防事故